The COVID-19 pandemic was a major disruptive force to propel major innovation, scale, and capacity building in vaccine development. The last two years have seen an unprecedented acceleration in vaccine research, regulatory approvals, and consumer readiness. In a panel discussion titled “Future of Vaccines’,  at the Financial Times Global Pharmaceutical and Biotechnology Conference, industry experts shared their lessons from the COVID-19 pandemic.

The panel, moderated by Greg Reh, Global Life Sciences and Healthcare Industry leader, Deloitte, comprised of

Judy Stewart, Senior Vice President, Head of US vaccines, GlaxoSmithKline Lovisa Afzelius, Origination Partner, Flagship Pioneering Nell Beattie, Chief Business Officer, VBI Vaccines Rasmus Bech Hansen, Co-Founder, and CEO, Airfinity